Galmed Pharmaceuticals (NASDAQ:GLMD) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Galmed Pharmaceuticals (NASDAQ:GLMD) from a hold rating to a sell rating in a report issued on Saturday morning.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ:GLMD opened at $1.27 on Friday. Galmed Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $23.80. The firm has a fifty day moving average of $1.70 and a 200 day moving average of $1.68. The firm has a market capitalization of $2.10 million, a PE ratio of -0.08 and a beta of 0.56.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 76.14% of the stock is currently owned by institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.